Antiverse

Antiverse is a biotechnology company that operates at the intersection of machine learning and antibody discovery. The company has developed a computational platform that designs and develops antibodies, with a particular focus on challenging drug targets such as G-protein coupled receptors (GPCRs) and ion channels, which are traditionally difficult to address.

The core of its business is an AI-augmented drug discovery solution that integrates with next-generation sequencing (NGS) to analyze data from existing lab workloads. This platform is utilized by pharmaceutical companies to accelerate the development of new therapies. The business model appears to be B2B, providing its specialized platform and services to other companies in the pharmaceutical and biotechnology sectors. By enabling the creation of antibodies for difficult targets, the company helps its clients to bring new drugs to market more quickly.

Keywords: antibody design, drug discovery, machine learning, G-protein coupled receptors, ion channels, computational platform, biotechnology, pharmaceutical, next-generation sequencing, therapeutic antibodies